Brilliant Blue G improves cognition in an animal model of Alzheimer's disease and inhibits amyloid-β-induced loss of filopodia and dendrite spines in hippocampal neurons

Neuroscience

Volumn 279, Issue , 2014, Pages 94-101

  Chen, X ^a   Hu, J ^a   Jiang, L ^a   Xu, S ^a   Zheng, B ^a   Wang, C ^a   Zhang, J ^a   Wei, X ^a   Chang, L ^a   Wang, Q ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid; Hippocampus; Memory; Purinergic

Indexed keywords

AMYLOID BETA PROTEIN; BRILLIANT BLUE G; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); COOMASSIE BRILLIANT BLUE; FUCHSINE; NOOTROPIC AGENT; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CELL DENSITY; CELL STRUCTURE; CELLULAR PARAMETERS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DENDRITIC SPINE; DRUG MECHANISM; FILOPODIA; FILOPODIA LENGTH; HIPPOCAMPAL NEURONAL CULTURE; LEARNING DISORDER; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PROTEIN DEPLETION; RAT; ALZHEIMER DISEASE; ANIMAL; CELL CULTURE; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; HIPPOCAMPUS; INSTITUTE FOR CANCER RESEARCH MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSEUDOPODIUM; SPATIAL MEMORY; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; COGNITION; COGNITION DISORDERS; DENDRITIC SPINES; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PSEUDOPODIA; RATS, SPRAGUE-DAWLEY; ROSANILINE DYES; SPATIAL MEMORY;

EID: 84907482756     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.08.036     Document Type: Article

References (32)

1. Chen X., Lin R., Chang L., Xu S., Wei X., Zhang J., Wang C., Anwyl R., Wang Q. Enhancement of long-term depression by soluble amyloid beta protein in rat hippocampus is mediated by metabotropic glutamate receptor and involves activation of p38MAPK, STEP and caspase-3. Neuroscience 2013, 253:435-443.
2. Chrovian C.C., Rech J.C., Bhattacharya A., Letavic M.A. P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders. Prog Med Chem 2014, 53:65-100.
3. Chu K., Yin B., Wang J., Peng G., Liang H., Xu Z., Du Y., Fang M., Xia Q., Benyan L. Inhibition of P2X7 receptor ameliorates transient global cerebral ischemia/reperfusion injury via modulating inflammatory responses in the rat hippocampus. J Neuroinflamm 2012, 9:69.
4. Diaz-Hernandez M., Diez-Zaera M., Sanchez-Nogueiro J., Gomez-Villafuertes R., Canals J.M., Alberch J., Miras-Portugal M.T., Lucas J.J. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J 2009, 23:1893-1906.
5. Diaz-Hernandez J.I., Gomez-Villafuertes R., Leon-Otegui M., Hontecillas-Prieto L., Del Puerto A., Trejo J.L., Lucas J.J., Garrido J.J., Gualix J., Miras-Portugal M.T., Diaz-Hernandez M. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3beta and secretases. Neurobiol Aging 2012, 33:1816-1828.
6. Gandelman M., Peluffo H., Beckman J.S., Cassina P., Barbeito L. Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J Neuroinflamm 2010, 7:33.
7. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
8. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., Spires-Jones T.L. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009, 106:4012-4017.
9. Koffie R.M., Hyman B.T., Spires-Jones T.L. Alzheimer's disease: synapses gone cold. Mol Neurodegen 2011, 6:63.
10. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007, 27:796-807.
11. Lee H.G., Won S.M., Gwag B.J., Lee Y.B. Microglial P2X(7) receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse model of Alzheimer's disease. Exp Mol Med 2011, 43:7-14.
12. Li S., Jin M., Koeglsperger T., Shepardson N.E., Shankar G.M., Selkoe D.J. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011, 31:6627-6638.
13. Ma T., Klann E. Amyloid beta: linking synaptic plasticity failure to memory disruption in Alzheimer's disease. J Neurochem 2012, 120(suppl. 1):140-148.
14. Marchetti C., Marie H. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models?. Rev Neurosci 2011, 22:373-402.
15. McLarnon J.G., Ryu J.K., Walker D.G., Choi H.B. Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol 2006, 65:1090-1097.
16. Meraz-Rios M.A., Toral-Rios D., Franco-Bocanegra D., Villeda-Hernandez J., Campos-Pena V. Inflammatory process in Alzheimer's Disease. Front Integr Neurosci 2013, 7:59.
17. Neugroschl J., Sano M. Current treatment and recent clinical research in Alzheimer's disease. Mount Sinai J Med 2010, 77:3-16.
18. Ni J., Wang P., Zhang J., Chen W., Gu L. Silencing of the P2X(7) receptor enhances amyloid-beta phagocytosis by microglia. Biochem Biophys Res Commun 2013, 434:363-369.
19. Parvathenani L.K., Tertyshnikova S., Greco C.R., Roberts S.B., Robertson B., Posmantur R. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem 2003, 278:13309-13317.
20. Peng W., Cotrina M.L., Han X., Yu H., Bekar L., Blum L., Takano T., Tian G.F., Goldman S.A., Nedergaard M. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci USA 2009, 106:12489-12493.
21. Querfurth H.W., LaFerla F.M. Alzheimer's disease. New Engl J Med 2010, 362:329-344.
22. Rampe D., Wang L., Ringheim G.E. P2X7 receptor modulation of beta-amyloid- and LPS-induced cytokine secretion from human macrophages and microglia. J Neuroimmunol 2004, 147:56-61.
23. Ryu J.K., McLarnon J.G. Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer's disease. Neuroreport 2008, 19:1715-1719.
24. Sanz J.M., Chiozzi P., Ferrari D., Colaianna M., Idzko M., Falzoni S., Fellin R., Trabace L., Di Virgilio F. Activation of microglia by amyloid beta requires P2X7 receptor expression. J Immunol 2009, 182:4378-4385.
25. Skaper S.D., Debetto P., Giusti P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J 2010, 24:337-345.
26. Takenouchi T., Sekiyama K., Sekigawa A., Fujita M., Waragai M., Sugama S., Iwamaru Y., Kitani H., Hashimoto M. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz) 2010, 58:91-96.
27. Volonte C., Apolloni S., Skaper S.D., Burnstock G. P2X7 receptors: channels, pores and more. CNS Neurol Disord Drug Targets 2012, 11:705-721.
28. Wang Q.W., Rowan M.J., Anwyl R. Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway. Neurobiol Aging 2009, 30:1608-1613.
29. Weisman G.A., Camden J.M., Peterson T.S., Ajit D., Woods L.T., Erb L. P2 receptors for extracellular nucleotides in the central nervous system: role of P2X7 and P2Y(2) receptor interactions in neuroinflammation. Mol Neurobiol 2012, 46:96-113.
30. Wong H.E., Qi W., Choi H.M., Fernandez E.J., Kwon I. A safe, blood-brain barrier permeable triphenylmethane dye inhibits amyloid-beta neurotoxicity by generating nontoxic aggregates. ACS Chem Neurosci 2011, 2:645-657.
31. Xu S., Guan Q., Wang C., Wei X., Chen X., Zheng B., An P., Zhang J., Chang L., Zhou W., Mody I., Wang Q. Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses. Neurosci Lett 2014, 578:7-11.
32. Yu Q., Guo Z., Liu X., Ouyang Q., He C., Burnstock G., Yuan H., Xiang Z. Block of P2X7 receptors could partly reverse the delayed neuronal death in area CA1 of the hippocampus after transient global cerebral ischemia. Purinergic Signal 2013, 9:663-675.